TargetRx and Skura Corp. have launched a new integrated solution combining the physician-level targeting power of TargetAdvantage with Skura’s SFX Sales Enablement Solution. The tool offers sales teams seamless and immediate access to critical TargetAdvantage data through the SFX Sales Enablement tool, enabling them to better understand prescribing behavior by focusing on an individual physician’s needs and motivations.
“The factors that influence a physician’s decision to select one drug or treatment over another – product attributes, promotion types, patient requests, and payer...
In an exclusive interview with Med Ad News, the recently appointed Teva CEO discusses his new job, his company's strengths, and his vision of the industry's future.
In a few months Abbott Laboratories will become two companies - and the new research-based pharmaceutical half with boast the world's best-selling prescription product.
While the rest of the industry plays defense, no pharmaceutical company in the world has grown quite like Teva in the past decade.
The new Merck's identity is coming into focus, as the company's latest generation of blockbuster products moves to the top of its sales charts and its list of partnerships continues to grow.
With the loss of Zyprexa and pending losses of Cymbalta and Humalog, leaders at Eli Lilly and Co. are buckling down for a bumpy ride.
The leaders of Bristol-Myers Squibb are hoping that a group of fast-growing products and an aggressive strategy of acquisition and partnership can keep the company afloat after the loss of its most successful brand.
Teva Pharmaceutical Industries Ltd. has announced the appointments of Dr. Carlo De Notaristefani as president and CEO of global operations, and Aharon (Arik) Yaari as the executive VP to the newly created organization, Community and Institutional Affairs. Both Dr. De Notaristefani and Mr. Yaari will report directly to Dr. Jeremy Levin, president and CEO of Teva Pharmaceutical Industries, and will join the company’s executive team.
“We are delighted to have Carlo and Arik in these roles,” Dr. Levin says. “Through its founding days in Israel the company has prided itself on the...
? James Rae is appointed independent chairman of the board of directors, Bioniche Life Sciences Inc. Mr. Rae has been the CEO of Viron Therapeutics Inc. since 2007 and has more than 30 years of experience in the manufacturing, marketing, financial, and R&D operations of both pharmaceutical and biotechnology companies. Also, Cameron Groome, executive VP, corporate and strategic development; Jim Phillips, senior VP, industry relations; Dr. Dragan Rogan, chief veterinary scientific officer; and Dr. Gary Weber, president, Bioniche Food Safety (U.S.) have...
For the third year, Med Ad News has surveyed its readership to develop a picture of the current working environment for companies in and around the pharmaceutical space.